Is IMRX or MGTX more profitable?

MeiraGTx has a net margin of 19.87% compared to Immuneering's net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% MeiraGTx 19.87% 283.85% 29.39%

Does the media favor IMRX or MGTX?

In the previous week, MeiraGTx had 4 more articles in the media than Immuneering. MarketBeat recorded 8 mentions for MeiraGTx and 4 mentions for Immuneering. MeiraGTx's average media sentiment score of 0.52 beat Immuneering's score of -0.22 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is AKTS or IMRX more profitable?

Aktis Oncology's return on equity of 0.00% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Immuneering N/A -27.15% -25.75%

Does the media favor AKTS or IMRX?

In the previous week, Aktis Oncology and Aktis Oncology both had 4 articles in the media. Aktis Oncology's average media sentiment score of 0.45 beat Immuneering's score of -0.22 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, IMRX or SVRA?

Savara is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.04 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is IMRX or SVRA more profitable?

Immuneering's return on equity of -27.15% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% Savara N/A -90.28% -68.95%

Does the media prefer IMRX or SVRA?

In the previous week, Immuneering and Immuneering both had 4 articles in the media. Savara's average media sentiment score of 0.60 beat Immuneering's score of -0.22 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate IMRX or CVAC?

Immuneering currently has a consensus price target of $15.71, suggesting a potential upside of 286.10%. Given Immuneering's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immuneering is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, IMRX or CVAC?

CureVac has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.04 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Is IMRX or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Immuneering's net margin of 0.00%. CureVac's return on equity of -23.03% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -27.15% -25.75% CureVac 199.92% -23.03% -19.09%

Does the media refer more to IMRX or CVAC?

In the previous week, Immuneering had 3 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Immuneering and 1 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Immuneering's score of -0.22 indicating that CureVac is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral CureVac 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is JANX or IMRX more profitable?

Janux Therapeutics' return on equity of -11.89% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Immuneering N/A -27.15% -25.75%

Does the media refer more to JANX or IMRX?

In the previous week, Janux Therapeutics and Janux Therapeutics both had 4 articles in the media. Janux Therapeutics' average media sentiment score of 0.44 beat Immuneering's score of -0.22 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Immuneering (IMRX) Competitors

$4.07 +0.04 (+0.99%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.09 +0.02 (+0.39%)

As of 10/2/2026 07:48 PM Eastern

Compare

IMRX vs. MGTX, AKTS, SVRA, CVAC, and JANX

Should you buy Immuneering stock or one of its competitors? Immuneering's main competitors and comparable companies include MeiraGTx (MGTX), Aktis Oncology (AKTS), Savara (SVRA), CureVac (CVAC), and Janux Therapeutics (JANX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immuneering compare to MeiraGTx?

Immuneering (NASDAQ:IMRX) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Immuneering presently has a consensus price target of $15.71, suggesting a potential upside of 286.10%. MeiraGTx has a consensus price target of $24.71, suggesting a potential upside of 129.05%. Given Immuneering's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immuneering is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

Immuneering has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

Immuneering has higher earnings, but lower revenue than MeiraGTx. Immuneering is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
MeiraGTx	$81.39M	12.73	-$114.20M	$0.71	15.20

MeiraGTx has a net margin of 19.87% compared to Immuneering's net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
MeiraGTx	19.87%	283.85%	29.39%

In the previous week, MeiraGTx had 4 more articles in the media than Immuneering. MarketBeat recorded 8 mentions for MeiraGTx and 4 mentions for Immuneering. MeiraGTx's average media sentiment score of 0.52 beat Immuneering's score of -0.22 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 14.9% of Immuneering shares are owned by company insiders. Comparatively, 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

MeiraGTx beats Immuneering on 10 of the 16 factors compared between the two stocks.

How does Immuneering compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Aktis Oncology's return on equity of 0.00% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Immuneering	N/A	-27.15%	-25.75%

Aktis Oncology currently has a consensus price target of $35.63, indicating a potential upside of 92.36%. Immuneering has a consensus price target of $15.71, indicating a potential upside of 286.10%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Aktis Oncology and Aktis Oncology both had 4 articles in the media. Aktis Oncology's average media sentiment score of 0.45 beat Immuneering's score of -0.22 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by company insiders. Comparatively, 14.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immuneering has lower revenue, but higher earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	153.15	-$63.73M	-$0.82	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

Summary

Immuneering beats Aktis Oncology on 7 of the 13 factors compared between the two stocks.

How does Immuneering compare to Savara?

Immuneering (NASDAQ:IMRX) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

In the previous week, Immuneering and Immuneering both had 4 articles in the media. Savara's average media sentiment score of 0.60 beat Immuneering's score of -0.22 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Savara has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 14.9% of Immuneering shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Immuneering currently has a consensus target price of $15.71, indicating a potential upside of 286.10%. Savara has a consensus target price of $10.00, indicating a potential upside of 107.90%. Given Immuneering's stronger consensus rating and higher probable upside, equities research analysts clearly believe Immuneering is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Savara is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Immuneering's return on equity of -27.15% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Savara	N/A	-90.28%	-68.95%

Summary

Immuneering beats Savara on 9 of the 13 factors compared between the two stocks.

How does Immuneering compare to CureVac?

Immuneering (NASDAQ:IMRX) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Immuneering had 3 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Immuneering and 1 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Immuneering's score of -0.22 indicating that CureVac is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
CureVac	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CureVac has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

67.7% of Immuneering shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 14.9% of Immuneering shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Immuneering's net margin of 0.00%. CureVac's return on equity of -23.03% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
CureVac	199.92%	-23.03%	-19.09%

Immuneering has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Immuneering currently has a consensus price target of $15.71, suggesting a potential upside of 286.10%. Given Immuneering's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immuneering is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CureVac beats Immuneering on 9 of the 16 factors compared between the two stocks.

How does Immuneering compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Janux Therapeutics currently has a consensus target price of $36.46, suggesting a potential upside of 115.37%. Immuneering has a consensus target price of $15.71, suggesting a potential upside of 286.10%. Given Immuneering's stronger consensus rating and higher possible upside, analysts clearly believe Immuneering is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Janux Therapeutics' return on equity of -11.89% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Immuneering	N/A	-27.15%	-25.75%

Janux Therapeutics has a beta of 2.4, indicating that its stock price is 140% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Immuneering has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	103.51	-$113.62M	-$1.64	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

In the previous week, Janux Therapeutics and Janux Therapeutics both had 4 articles in the media. Janux Therapeutics' average media sentiment score of 0.44 beat Immuneering's score of -0.22 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 14.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Janux Therapeutics and Immuneering tied by winning 7 of the 14 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRX vs. The Competition

Export

Metric	Immuneering	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$263.32M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-3.91	13.06	275.66	26.04
Price / Sales	N/A	1,295.79	609.46	91.89
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	1.20	16.63	10.93	6.31
Net Income	-$56.03M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-4.68%	-2.99%	-2.00%	-1.66%
1 Month Performance	-19.25%	-10.60%	-6.15%	-4.50%
1 Year Performance	-32.73%	19.44%	7.44%	2.06%

Immuneering Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRX Immuneering	2.1241 of 5 stars	$4.07 +1.0%	$15.71 +286.1%	-37.7%	$263.32M	N/A	N/A	57	News Coverage
MGTX MeiraGTx	3.6415 of 5 stars	$11.08 -0.2%	$24.71 +123.0%	+28.5%	$1.06B	$81.39M	15.59	393	News Coverage
AKTS Aktis Oncology	2.4913 of 5 stars	$19.59 +1.2%	$35.63 +81.8%	N/A	$1.06B	$6.50M	N/A	79	News Coverage Positive News Analyst Forecast
SVRA Savara	1.8033 of 5 stars	$5.09 +0.3%	$10.00 +96.7%	+37.8%	$1.05B	N/A	N/A	70
CVAC CureVac	0.0737 of 5 stars	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuneering (IMRX) Competitors

IMRX vs. MGTX, AKTS, SVRA, CVAC, and JANX

How does Immuneering compare to MeiraGTx?

Summary

How does Immuneering compare to Aktis Oncology?

Summary

How does Immuneering compare to Savara?

Summary

How does Immuneering compare to CureVac?

Summary

How does Immuneering compare to Janux Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuneering (IMRX) Competitors

IMRX vs. MGTX, AKTS, SVRA, CVAC, and JANX

How does Immuneering compare to MeiraGTx?

Do analysts recommend IMRX or MGTX?

Which has more volatility and risk, IMRX or MGTX?

Which has better valuation & earnings, IMRX or MGTX?

Is IMRX or MGTX more profitable?

Does the media favor IMRX or MGTX?

Do insiders and institutionals hold more shares of IMRX or MGTX?

Summary

How does Immuneering compare to Aktis Oncology?

Is AKTS or IMRX more profitable?

Do analysts rate AKTS or IMRX?

Does the media favor AKTS or IMRX?

Do insiders & institutionals have more ownership in AKTS or IMRX?

Which has preferable earnings & valuation, AKTS or IMRX?

Summary

How does Immuneering compare to Savara?

Does the media prefer IMRX or SVRA?

Which has more risk and volatility, IMRX or SVRA?

Do institutionals and insiders have more ownership in IMRX or SVRA?

Do analysts recommend IMRX or SVRA?

Which has better valuation and earnings, IMRX or SVRA?

Is IMRX or SVRA more profitable?

Summary

How does Immuneering compare to CureVac?

Does the media refer more to IMRX or CVAC?

Which has higher earnings & valuation, IMRX or CVAC?

Do insiders & institutionals believe in IMRX or CVAC?

Is IMRX or CVAC more profitable?

Which has more risk and volatility, IMRX or CVAC?

Do analysts rate IMRX or CVAC?

Summary

How does Immuneering compare to Janux Therapeutics?

Do analysts prefer JANX or IMRX?

Is JANX or IMRX more profitable?

Which has more volatility and risk, JANX or IMRX?

Which has stronger earnings & valuation, JANX or IMRX?

Does the media refer more to JANX or IMRX?

Do institutionals & insiders hold more shares of JANX or IMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools